#Biotech M&A

The Cas12 Consolidation: Why the Mid-Cap Biotech Merger Wave Signals a New Era for Genomic Medicine

While the market's attention remains fixed on GLP-1 weight-loss drug sales, a quiet wave of consolidations among CRISPR-Cas12 innovators is creating a new tier of 'Genomic Platform Giants.' This strategic shift marks the end of the 'Single-Molecule' era and the beginning of the integrated genomic utility model.